Drug intelligence / Profile preview

BGC20-0582

Development stage: Phase 2
Lead developer: Boston Scientific
Modality: Small Molecules
Administration: Topical

Overview

BGC20-0582 is a small molecule drug developed as a topical gel for the treatment of head lice infestation (Pediculus capitis). It was originally developed by BTG International and later associated with Boston Scientific following acquisition. The drug reached Phase 2 clinical trials for the indication of head lice but has not been approved or marketed. Its precise mechanism of action remains unknown, and it is described as a naturally derived product formulated for topical administration to eradicate lice infestations[1][3][4][5].

Other names: Head lice treatment BTG

Beyond the preview

Go deeper on BGC20-0582.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGC20-0582.

Explore the full profile